| 词条 | Valneva SE |
| 释义 |
| name = Valneva SE | type = Societas Europaea | traded_as = Euronext: VLA | foundation = 2013 | location_city = Saint-Herblain | location_country = France | key_people = Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board) | industry = Biotechnology | fate = established through a merger of former Intercell and Vivalis SA | products = Development of vaccines | homepage = {{URL|http://www.valneva.com/}} }}Valneva SE is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva was founded in 2013 through the merger of Intercell and Vivalis SA.[1] It has been listed on the Vienna Stock Exchange and Euronext since May 28, 2013. Marketed vaccines generated by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia)[2] and Dukoral, a vaccine against cholera (approved in Europe, America and Australia)[3] Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas Aeruginosa,[4] V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck),[5] and IC41, therapeutic vaccine against hepatitis C[6] References1. ^{{cite web|url=https://www.wienerborse.at/en/market-data/shares-others/company-profile/?ISIN=FR0011472943&cHash=3303ec5a99fb5aff7afad63aebe25ee7|title=Valneva SE company profile, wiener börse|accessdate=2017-09-02}} 2. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000963/human_med_000862.jsp&mid=WC0b01ac058001d124|title= Ixiaro, Japanese-encephalitis vaccine (inactivated, adsorbed)|publisher=European Medicines Agency (EMA)|date=2009-06-05|accessdate=2017-04-25}} 3. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000476/human_med_000745.jsp&mid=WC0b01ac058001d124|title= Dukoral, cholera vaccine (inactivated, oral)|publisher=European Medicines Agency (EMA)|date=2009-04-30|accessdate=2017-04-25}} 4. ^{{cite web|url=http://www.fiercebiotech.com/biotech/valneva-writes-off-hospital-acquired-infection-vaccine-following-phii-iii-miss|title=Valneva writes off hospital-acquired infection vaccine following PhII/III miss|publisher=FierceBiotech, Questex LLC.|date=2016-09-01|accessdate=2017-04-25}} 5. ^{{cite web|url= https://www.reuters.com/article/us-intercell-merck-idUSTRE75711P20110608|title= Merck ends trial of Intercell's MRSA vaccine|publisher=Reuters|date=2011-06-08|accessdate=2017-04-25}} 6. ^{{cite web|url=http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614|title=Intercell Hepatitis C Vaccine Meets Primary Endpoints|publisher=FDA News|date=2007-08-22|accessdate=2008-08-15}} External links
4 : Companies based in Lyon|Companies based in Vienna|Biotechnology companies|Companies established in 2013 |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。